Abiraterone acetate is under clinical development by Tavanta Therapeutics and currently in Phase III for Hormone-Sensitive Prostate Cancer. According to GlobalData, Phase III drugs for Hormone-Sensitive Prostate Cancer have an 83% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Abiraterone acetate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Abiraterone acetate overview
Abiraterone acetate (DRGT-45) is under development for the treatment of metastatic castration-resistant prostate cancer and castrate-sensitive prostate cancer. It is administered through granules for oral suspension. It acts by targeting CYP17. The drug candidate is developed based on Super-API technology.
See Also:
Tavanta Therapeutics overview
Tavanta Therapeutics is a pharmaceutical company that develops proprietary drugs to treat patients with debilitating or serious diseases with novel small molecules and peptides. The company is headquartered in King of Prussia, Pennsylvania, the US.
For a complete picture of Abiraterone acetate’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
